tiprankstipranks
Roivant Sciences Ltd. (DE:87S)
NASDAQ:87S
Germany Market
87S
Roivant Sciences
RESEARCH TOOLSreports

Roivant Sciences (87S) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

87S Analyst Ratings

Strong Buy
7Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Roivant
Sciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

87S Stock 12 Month Forecast

Average Price Target

€31.57
▲(28.84% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Roivant Sciences in the last 3 months. The average price target is €31.57 with a high forecast of €36.71 and a low forecast of €25.60. The average price target represents a 28.84% change from the last price of €24.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"€8","37":"€37","15.25":"€15.25","22.5":"€22.5","29.75":"€29.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36.71238816,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€36.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.566410214171423,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€31.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.6025202192,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€25.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,15.25,22.5,29.75,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.02,31.457876012307693,31.895752024615383,32.33362803692308,32.77150404923077,33.20938006153846,33.64725607384616,34.08513208615385,34.52300809846154,34.960884110769236,35.398760123076926,35.836636135384616,36.27451214769231,{"y":36.71238816,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.02,31.06203155493626,31.104063109872527,31.14609466480879,31.188126219745055,31.230157774681317,31.27218932961758,31.314220884553844,31.356252439490106,31.398283994426368,31.440315549362634,31.482347104298896,31.52437865923516,{"y":31.566410214171423,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.02,30.603270786092306,30.186541572184616,29.769812358276923,29.35308314436923,28.936353930461536,28.519624716553846,28.102895502646152,27.686166288738463,27.26943707483077,26.852707860923076,26.435978647015382,26.019249433107692,{"y":25.6025202192,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.366,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.496,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.455,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.165,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.04,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.54,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.21,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.02,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€36.71Average Price Target€31.57Lowest Price Target€25.60
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on DE:87S
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€34.96
Buy
42.71%
Upside
Reiterated
06/16/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (NASDAQ: ENGN), Medtronic (NYSE: MDT) and Roivant Sciences (NASDAQ: ROIV)
Guggenheim Analyst forecast on DE:87S
Yatin Suneja
Guggenheim
Guggenheim
€26.22→€31.47
Buy
28.44%
Upside
Reiterated
05/26/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Crescent Biopharma (NASDAQ: CBIO) and Genmab (NASDAQ: GMAB)
J.P. Morgan Analyst forecast on DE:87S
Brian Cheng
J.P. Morgan
J.P. Morgan
€30.59→€34.96
Buy
42.71%
Upside
Reiterated
05/26/26
Roivant Sciences price target raised to $40 from $35 at JPMorganRoivant Sciences price target raised to $40 from $35 at JPMorgan
Bank of America Securities Analyst forecast on DE:87S
Chi Meng Fong
Bank of America Securities
Bank of America Securities
€25.79→€27.53
Hold
12.38%
Upside
Reiterated
05/25/26
Roivant Sciences price target raised to $31.50 from $29.50 at BofARoivant Sciences price target raised to $31.50 from $29.50 at BofA
H.C. Wainwright Analyst forecast on DE:87S
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
€29.72
Buy
21.30%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Kindly MD (NASDAQ: NAKA) and Roivant Sciences (NASDAQ: ROIV)
Citi Analyst forecast on DE:87S
Samantha Semenkow
Citi
Citi
€30.59→€36.71
Buy
49.85%
Upside
Reiterated
05/21/26
Roivant Sciences price target raised to $42 from $35 at CitiRoivant Sciences price target raised to $42 from $35 at Citi
TD Cowen Analyst forecast on DE:87S
Yaron Werber
TD Cowen
TD Cowen
€25.6
Buy
4.50%
Upside
Assigned
05/18/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV) and Citius Oncology (NASDAQ: CTOR)
Goldman Sachs Analyst forecast on DE:87S
Corinne Johnson
Goldman Sachs
Goldman Sachs
€33.22→€35.84
Buy
46.28%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Ovid Therapeutics (NASDAQ: OVID) and Legend Biotech (NASDAQ: LEGN)
Bernstein Analyst forecast on DE:87S
William Pickering
Bernstein
Bernstein
€30.59
Buy
24.87%
Upside
Initiated
03/20/26
Roivant Sciences initiated with an Outperform at BernsteinRoivant Sciences initiated with an Outperform at Bernstein
Jefferies Analyst forecast on DE:87S
Dennis Ding
Jefferies
Jefferies
€20.98→€26.22
Buy
7.03%
Upside
Reiterated
02/09/26
Roivant Sciences price target raised to $30 from $24 at JefferiesRoivant Sciences price target raised to $30 from $24 at Jefferies
Leerink Partners Analyst forecast on DE:87S
David Risinger
Leerink Partners
Leerink Partners
€19.23→€27.97
Buy
14.17%
Upside
Reiterated
12/15/25
Roivant Sciences: Promising Future with Strong Pipeline and Financial Stability
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on DE:87S
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€34.96
Buy
42.71%
Upside
Reiterated
06/16/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: enGene Holdings (NASDAQ: ENGN), Medtronic (NYSE: MDT) and Roivant Sciences (NASDAQ: ROIV)
Guggenheim Analyst forecast on DE:87S
Yatin Suneja
Guggenheim
Guggenheim
€26.22→€31.47
Buy
28.44%
Upside
Reiterated
05/26/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Crescent Biopharma (NASDAQ: CBIO) and Genmab (NASDAQ: GMAB)
J.P. Morgan Analyst forecast on DE:87S
Brian Cheng
J.P. Morgan
J.P. Morgan
€30.59→€34.96
Buy
42.71%
Upside
Reiterated
05/26/26
Roivant Sciences price target raised to $40 from $35 at JPMorganRoivant Sciences price target raised to $40 from $35 at JPMorgan
Bank of America Securities Analyst forecast on DE:87S
Chi Meng Fong
Bank of America Securities
Bank of America Securities
€25.79→€27.53
Hold
12.38%
Upside
Reiterated
05/25/26
Roivant Sciences price target raised to $31.50 from $29.50 at BofARoivant Sciences price target raised to $31.50 from $29.50 at BofA
H.C. Wainwright Analyst forecast on DE:87S
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
€29.72
Buy
21.30%
Upside
Reiterated
05/21/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Kindly MD (NASDAQ: NAKA) and Roivant Sciences (NASDAQ: ROIV)
Citi Analyst forecast on DE:87S
Samantha Semenkow
Citi
Citi
€30.59→€36.71
Buy
49.85%
Upside
Reiterated
05/21/26
Roivant Sciences price target raised to $42 from $35 at CitiRoivant Sciences price target raised to $42 from $35 at Citi
TD Cowen Analyst forecast on DE:87S
Yaron Werber
TD Cowen
TD Cowen
€25.6
Buy
4.50%
Upside
Assigned
05/18/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV) and Citius Oncology (NASDAQ: CTOR)
Goldman Sachs Analyst forecast on DE:87S
Corinne Johnson
Goldman Sachs
Goldman Sachs
€33.22→€35.84
Buy
46.28%
Upside
Reiterated
04/15/26
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (NASDAQ: ROIV), Ovid Therapeutics (NASDAQ: OVID) and Legend Biotech (NASDAQ: LEGN)
Bernstein Analyst forecast on DE:87S
William Pickering
Bernstein
Bernstein
€30.59
Buy
24.87%
Upside
Initiated
03/20/26
Roivant Sciences initiated with an Outperform at BernsteinRoivant Sciences initiated with an Outperform at Bernstein
Jefferies Analyst forecast on DE:87S
Dennis Ding
Jefferies
Jefferies
€20.98→€26.22
Buy
7.03%
Upside
Reiterated
02/09/26
Roivant Sciences price target raised to $30 from $24 at JefferiesRoivant Sciences price target raised to $30 from $24 at Jefferies
Leerink Partners Analyst forecast on DE:87S
David Risinger
Leerink Partners
Leerink Partners
€19.23→€27.97
Buy
14.17%
Upside
Reiterated
12/15/25
Roivant Sciences: Promising Future with Strong Pipeline and Financial Stability
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ASNDAscendis Pharma
CRBPCorbus Pharmaceuticals
ACHVAchieve Life Sciences
CELCCelcuity
GKOSGlaukos
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Roivant Sciences

3 Months
Brian ChengJ.P. Morgan
Success Rate
16/20 ratings generated profit
80%
Average Return
+20.36%
Copying Brian Cheng's trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +20.36% per trade.
1 Year
David RisingerLeerink Partners
Success Rate
32/35 ratings generated profit
91%
Average Return
+73.61%
Copying David Risinger's trades and holding each position for 1 Year would result in 91.43% of your transactions generating a profit, with an average return of +73.61% per trade.
2 Years
Yaron WerberTD Cowen
Success Rate
20/20 ratings generated profit
100%
Average Return
+136.87%
Copying Yaron Werber's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +136.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

87S Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
13
17
16
11
7
Hold
2
2
3
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
19
19
13
9
In the current month, 87S has received 7 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 87S average Analyst price target in the past 3 months is 31.57.
Each month's total comprises the sum of three months' worth of ratings.

87S Financial Forecast

87S Earnings Forecast

Next quarter’s earnings estimate for 87S is -€0.25 with a range of -€0.41 to -€0.11. The previous quarter’s EPS was €0.24. 87S beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 87S has Performed in-line its overall industry.
Next quarter’s earnings estimate for 87S is -€0.25 with a range of -€0.41 to -€0.11. The previous quarter’s EPS was €0.24. 87S beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year 87S has Performed in-line its overall industry.

87S Sales Forecast

Next quarter’s sales forecast for 87S is €1.81M with a range of €0.00 to €4.38M. The previous quarter’s sales results were €2.21M. 87S beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 87S has Performed in-line its overall industry.
Next quarter’s sales forecast for 87S is €1.81M with a range of €0.00 to €4.38M. The previous quarter’s sales results were €2.21M. 87S beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year 87S has Performed in-line its overall industry.

87S Stock Forecast FAQ

What is DE:87S’s average 12-month price target, according to analysts?
Based on analyst ratings, Roivant Sciences Ltd.’s 12-month average price target is 31.57.
    What is DE:87S’s upside potential, based on the analysts’ average price target?
    Roivant Sciences Ltd. has 28.84% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Roivant Sciences Ltd. a Buy, Sell or Hold?
          Roivant Sciences Ltd. has a consensus rating of Strong Buy, which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Roivant Sciences Ltd.’s share price target?
            The average share price target for Roivant Sciences Ltd. is 31.57. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €36.71 ,and the lowest forecast is €25.60. The average share price target represents 28.84% Increase from the current price of €24.5.
              What do analysts say about Roivant Sciences Ltd.?
              Roivant Sciences Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of Roivant Sciences Ltd.?
                To buy shares of DE:87S, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.